Why Is Palantir Stock Falling? PLTR Slides 6.1% on NHS Scrutiny and Competition Concerns
Date: July 22, 2026
Key Takeaways
- Palantir stock closed 6.1% lower at $124.57 on July 22, extending an intraday decline that had initially been around 5%.
- Scrutiny of performance claims linked to Palantir’s NHS data platform and discussion of a popular open-source alternative weighed on sentiment.
- The wider weakness in software stocks and caution before Palantir’s August 3 earnings report amplified the sell-off.
Several Pressure Points Hit Palantir Stock at Once
Palantir Technologies (NASDAQ: PLTR) experienced a significant decline as investors reacted to a mix of regulatory, competitive, and market-wide concerns. The stock closed at $124.57, down 6.1% from the previous session, with trading volume reaching approximately 38.6 million shares.
UK Watchdog Questions NHS Platform Performance Claims
A primary concern arose from the scrutiny of NHS England's performance data related to the Federated Data Platform (FDP), which utilizes Palantir’s Foundry technology. The platform is designed to enhance hospital capacity planning and patient management.
While NHS England previously reported positive outcomes from the platform, the UK’s Office for Statistics Regulation questioned the context of these claims, leading to a caveat that the data could not establish direct cause-and-effect relationships. An independent academic assessment is expected to provide further insights.
This scrutiny does not imply that Palantir has lost its NHS contract, but it complicates the narrative around the platform's effectiveness, which is crucial for Palantir's growth strategy.
Greater Manchester Highlights a Domestic Alternative
The debate intensified with Greater Manchester's integrated care board showcasing a locally developed data infrastructure, which has opted not to use Palantir’s platform. This development raises concerns about future contract renewals and the potential for public-sector organizations to consider domestic alternatives, especially given the sensitive nature of healthcare data contracts.
Open-Source World Monitor Raises Competition Questions
Palantir's stock faced additional pressure from discussions surrounding World Monitor, an open-source intelligence dashboard available on GitHub. While not a direct competitor to Palantir’s offerings, the rise of such tools could impact investor perceptions, especially given Palantir's high valuation.
As of July 22, Palantir's trailing price-to-earnings ratio was around 140, making it sensitive to competition and growth concerns.
Wider Software Sell-Off Amplifies the Decline
The decline in Palantir's stock coincided with a broader downturn in the software sector, with the Nasdaq Composite and software-sector indices experiencing notable drops. This context of market caution contributed to the heightened sell-off of Palantir shares.
August 3 Earnings Put Growth and Valuation in Focus
Investors are now looking ahead to Palantir’s second-quarter results, set to be released on August 3. The company has projected quarterly revenue between $1.797 billion and $1.801 billion, with adjusted earnings expected around $0.33 per share. Given the strong operating momentum from the previous quarter, expectations are high, and any signs of slowing growth could further pressure the stock's valuation.
PLTR Stock Levels to Watch
Palantir’s recent low of $123.45 is a critical short-term support level. A sustained drop below this could shift focus to the stock’s June low near $106.37. Conversely, resistance is noted around $132 to $133, which the stock must recover to alleviate immediate technical pressure.
As of July 22, Palantir's stock is approximately 40% below its 52-week high of $207.52, reflecting a significant shift in investor sentiment towards high-valued AI software companies.
The sell-off appears driven by a combination of regulatory scrutiny, competitive pressures, valuation sensitivity, and broader market weakness, rather than any specific contract cancellations or negative financial guidance.